In this article we detail the kinetic changes that take place in the expression of immunologically important cell surface molecules by lymph-borne cells during in vivo immune responses and describe the consequences of these changes for the immunological functions of these cells. We used the unique advantages of the cannulated lymphatic model in the sheep (1) to integrate the physiological changes occurring in antigen-stimulated lymphoid tissue with lymph cell function . This experimental model has the potential to provide information on lymphoid and accessory cell function that is not readily gained with other systems. The approaches we have used involve the development of mAbs to molecules associated with immune cell function, the use of these monoclonals to measure the changes in immune cell phenotype that occur during in vivo immune responses, and correlation of these changes with alteration of in vitro immunological functions of afferent lymph dendritic cells (DC). ' The major advantage of the cannulated lymphatic model lies in the opportunity to access in vivo fractionated cell populations from distinct lymphoid compartments . To do this, the afferent lymphatics to, and the efferent lymphatics from single peripheral lymph nodes are cannulated and lymph is collected quantitatively over extended periods of time (often 3-4 wk).
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The cellular constituents of afferent lymph and efferent lymph are different (2) . Afferent lymph contains few cells (0.5-1 x 106/ml) but does include between 1 and 10% dendritic cells and <l0olo B cells. Efferent lymph contains 5-10-fold more cells, consisting of-301 7o B cells and 70% T cells (3) . No cells of the macrophage/monocyte or DC series occur in efferent lymph. Evidence for this comes from morphological observation (2) as well as from data that show that efferent cells are incapable of responding to soluble antigen in vitro without the addition of accessory cells (4) . Experiments described in a companion paper (5) demonstrated that DC isolated from sheep afferent lymph are able to associate with antigen injected in vivo and to present that antigen to antigen-specific T cells. Furthermore, they seem to have a unique role in the induction of primary immune responses (6) . In afferent lymph these cells can be defined as those with dendritic morphology that constitutively express MHC class II and CD1 (5, 7) . The major biological function of class II is known to be the binding of antigenic peptides and communication with the TCR (8) and CD4 (9) molecules on T helper/inducer populations .
The CDl family of molecules is expressed mainly by cortical thymocytes, B cells, and dendritic cells in several sites (10) . Within the thymus CD1 is thought to be covalently associated with the CD8 molecule and it is speculated to be involved in T cell selection (11) . 
Materials and Methods
Animals and Surgery. 1-yr-old blackface x firm crossbred sheep were obtained from IAGPR, Dryden, UK. Sheep were primed by intradermal injection of five human doses of Bacillus Calmette Guerin (BCG; Glaxo, Greenford, UK) and intramuscular injection of 1 mg OVA or sperm whale myoglobin (both Sigma Chemical Co., Poole, UK) in CFA. Prefemoral afferent (peripheral) lymph was collected by the ablation of the prefemoral lymph node and cannulation of the efferent duct 6 wk later (3) . This duct now contains afferent lymph and is known as a " pseudoafferent." Efferent lymph was collected by the chronic carnulation ofthe popliteal efferent duct (12) . This procedure is necessary because the yields from standard afferent lymphatic cannulations are always very low. Animals were allowed at least 7 d postoperative recovery before the start ofthe experiments . Lymph was collected quantitatively in sterile (siliconized) bottles containing heparin .
Cell Fractionation. Afferent lymph cells were fractionated into lymphocytes and dendritic cells by centrifugation over stepped metrizamide (Nygaard & Co., Oslo, Norway) gradients (13) . Purity of fractionation was always assessed by staining with the monoclonal anti-sheep CDl antibody, VPM 5 (5), as well as by using geimsa-stained cytospin smears. B and T cells were enumerated using FITC-conjugated mAbs to sheep X light chains (VPM 8) and the sheep analogue ofCD5, SBUTl (7). Efferent lymph T cells were isolated by nylon-wool (Type 200 ; Fenwall Laboratories, Deerfield, IL) fractionation (14) .
Flow Cytometry. Class II and CDl quantitation by flow cytometry was done using single batches of FITC-conjugated SW73 .2 or VPM 5 at 10 ttg/ml in HBSSd0 .1% BSA/0.01 M sodium azide. F(ab')2 of SW73.2 and IgM of VPM 5 were coupled to FITC at a wt/wt ratio of 100:1, protein/FITC) . SW73 .2 is a rat mAb specific for a nonpolymorphic determinant on sheep class II that reacts with the known products of all the expressed class II loci (15) . 106 cells of each cell population (afferent lymph dendritic cells and lymphocytes) were stained daily with 50 pl FITC-antibody. After a 30-min incubation at 4°C the cells were spun through 0.5 ml FCS, washed once, made to 0.5 ml with HBSS + 5o7o FCS, then fixed by the addition of 0.5 ml 15o' paraformaldehyde . Daily samples were stored at 40C for analysis at the end of the experiment. 104 cells were analyzed by flow cytometry using a Becton Dickenson & Co. (Mountain View, CA) FACS IV with a 488-nm argon laser. FITC (520 nm) emission was detected with the photomultiplier tube voltage set at 555 mV. Forward and side (90°) scatter amplification was linear, while FITC amplification was logarithmic (all 256 channels) . Antibody-negative cells were gated by reference to fixed cell samples reacted with a negative mAb. Within experiments, class II-positive controls were made by the daily staining of 2 x 105 BL20 cells, a cloned bovine leukosis cell line (16) . In all experiments BL20 had a modal channel number of 180 (178-186) when stained with FITC-SW73 .2 as detailed above . The data are expressed as relative fluorescence intensity (modal channel number) . The cell cycle state of the cells was assessed by using propidium iodide (PI; Sigma) using the methods of Vindelov et al. (17) . Cell couplets were gated out by using resting efferent lymph cells as the control.
Saturation Binding Studies. The quantitation of anti-class II antibody binding sites per cell was by saturation binding as described previously (15, 18) . Briefly, washed cells were made to 2 x 106/ml in RPMI 1640 + 10% FCS + 0.01 M sodium azide. 250 Etl of cell suspension were mixed with doubling dilutions of '25I-(Radiochemical Centre, Amersham, UK) labeled Fab' SW73.2 at 4°C . After a 2-h incubation, aliquots of the reaction mixture from each dilution were layered on to 200 141 phthalate (dibutyl/dionyl phthalate at a ratio of 4:1) in 0.4 ml microfuge tubes and centrifuged at 13,000 g for 5 min then snap frozen in liquid N2. The frozen microfuge tubes were then cut in order to separate the radioactivity associated with the cells from the unbound antibody. As with the flow cytometry experiments, these studies were controlled daily by measurements on the BL20 cell line (mean of 2 x 105 antibody binding sites per cell, variation 1.6-2.3 x 105). The proportion ofclass II-positive cells in each population was always considered when calculating the number of antibody binding sites per cell.
Purification ofMonoclonal Ig IgM fromVPM5 ascitic fluid (and ofthe mouse IgM anti-sheep class II mAb VPM 3) was purified by initial precipitation with ammonium sulphate at 45,70 saturation and then gel filtration using Sephacryl S300 (Pharmacia Fine Chemicals, Piscataway, NJ) . IgG2a and F(ab')2 isolation from SW73 .2 ascitic fluid were as described previously (15) . The Fab' fragment was produced from the F(aV)2 by reduction (10 mM dithiothreitol in 100 mM Tris, pH 8, for 1 h) and alkylation (30 mM iodoacetamide for 1 h). The F(ab')2 was purified on DEAE-cellulose (10 mM phosphate buffer, pH 7.5). The Fab' fragment was purified by gel filtration on Sephadex G200 superfine (Pharmacia Fine Chemicals) . Purified Ig of VPM 5 and F(ab')2 of SW73.2 for the proliferation assays was made to 100 t~g/ml in RPMI 1640 + 10% FCS before sterile filtration and storage at -70°C . Supernatants of an IgM anti-sheep class II (VPM 3), the anti-sheep CDl monoclonal SBUT6 (7) and the anti-bovine CDl antibodies CC13 and CC14 (19) used in the irk vitro assays were dialyzed against RPMI 1640, filter sterilized, then FCS was added to 10% .
Production ofAntigen-specific CellLines. Cell lines specific for the antigens OVA and purified protein derivative oftuberculin (PPD) were constructed as described by Bujdoso et al. (20) . Briefly, efferent lymphocytes were cultured at 2 x 106/ml in 24-well culture plates with RPMI 1640 + l0o7o FCS containing either OVA or PPD at 25 kg/ml . Irradiated PBM were added to 5 x 105/ml . After 7 d incubation, viable cells were harvested by LYMPHOPREP and further incubated for 14 d at 1 x 105/ml with 20 U human rIL-2 (a gift from Biogen SA, Basel, Switzerland) added every 3 d. Viable cells were again harvested and restimulated with antigen by culturing at 5 x 105 cells/ml with 1 x 106/ml irradiated, autologous PBM . After 7 d the cells were again harvested and expanded with IL-2 for 14 d. The viable cells were then cryopreserved in liquid N2 using a programmed cell freezer (Planar Products Ltd., London, UK).
In Vitro Proliferation Assays. Briefly, 104 antigen-specific T cells per well (in round-bottomed microtest trays ; Gibco-Biocult, Paisley, Scotland) were cultured with OVA, sperm whale myoglobin (both Sigma Chemical Co.) or PPD (batch 297 ; Central Veterinary Laboratories, Weybridge, UK) at a final concentration of25,ug/ml. APCs for soluble antigen-induced lymphocyte proliferation and MLR assays were 1 x 103 to 2.5 x 104 PBMC or afferent lymph DC irradiated with 3,000 rad -f-irradiation. PBMC were prepared by centrifugation over LYM-PHOPREP (Nygaard) . Responder cells in MLR assays were 2.5 x 104 allogeneic efferent lymph T cells purified by nylon-wool.
The effects of monoclonal anti-class II and anti-CD1 antibodies on in vitro proliferation and MLR assays were assessed by the addition of 20 p,l of SW73.2 and VPM 5 at dilutions of 0.01-100 Wg/ml . Supernatants of VPM 3, SBUT6, CC13, and CC14 were used at final concentrations of 1/2, 1/5, and 1/10. Experimental Protocol. A prefemoral "pseudoafferent" lymphatic was cannulated and 7 d later antigen was introduced into the drainage area by intradermal injection of 50 kg PPD, OVA, or -sperm whale myoglobin . Daily for 2 d before and for 8 d after in vivo antigenic challenge in both antigen-naive and in antigen-primed animals the levels of both MHC class Il and CDl expression by the purified DC were assessed by flow cytometry Quantitative expression of class II expression was also measured by a saturation binding technique. The immunological function of the DC was assessed by testing their ability to present soluble antigen (either OVA or PPD) to autologous OVA-specific or PPD-specific T cell lines and to stimulate allogenic efferent T cells in an MLR . The involvement of MHC class II and CDl in the alterations in DC function was studied by examining the effects ofmAbs to these molecules in these in vitro assays. 11 sheep were used (four with PPD and four with OVA and three with sperm whale myoglobin) to assess secondary antigenic challenge; while six (two for each antigen) sheep were used to compare the primary and secondary responses .
Results
Effect ofIn Vivo Antigenic Challenge on Afferent Cell Output . The changes in the percentage of class II-positive lymphocytes in afferent lymph during a secondary immune response to PPD can be seen in Fig . 1 a . The proportion of s1g" cells remains unaltered at N9% (6-12%) of the total, but class II-expressing T cells increase from Local antigenic stimulation also induces changes in lymph cell kinetics (Fig . 1  b) . Resting afferent lymph has a total cell output of between 6 and 10 x 10 6 cells/h, this falls three-to fivefold, to <2 x 106/h during days 1-3 because of a drop in lymph cell concentration. By day 5 the cell output increases >5-fold (to 5-8 x 107/h), partly because of a rise in lymph fluid flow rate . These changes are only transient however, as by 8-9 d after challenge the lymph cell phenotype and kinetics are similar to those in resting lymph. These changes are restricted to secondary responses. No detectable modulation of class II expression and cell kinetics occur during primary antigenic challenge in antigen-naive sheep.
Alteration in Afferent DC Expression of Class H. The rise in the proportion of class II-positive cells in afferent lymph during secondary responses is also accompanied by marked increases in the overall level of class II expression by single cells. Antibody binding studies have shown that DC constitutively express N3 x 10 5 MHC class II molecules per cell (assuming one antibody binding site per class II molecule) (variation between 2.3 and 3 .6 x 105), which doubles to N6 x 10 5 on day 3, and increases almost sixfold to 1.7 x 10 6 (1 .5-2 .1 x 106) in response to in vivo challenge with antigen (Fig. 2 a) . These figures were calculated by saturation binding, where 1 x 10 6 DC were reacted with dilutions of 125 1-labeled F(ab')2 SW73 .2, 1 /Ag antibody is 150,000 cpm. 1 x 106 DC from day 0 afferent labeled with 7,000 cpm at saturation (i .e., 3 x 10 5 molecules per cell), on day 3 they labeled with 15,000 cpm at saturation (6 x 10 5 molecules per cell), and on day 5 with 41,000 cpm at saturation (1 .7 x 10 6 molecules per cell). Cellular class II expression by lymphocytes is also increased, rising from a mean resting level of <1 x 10 5 (0 .5-1 .3 x 10 5) up to 2 .3 x 105 (1 .6-2 .6 x 10 5). These alterations are only transient, however (Fig . 2 b) , as quantitative class II expression of afferent cells returns to resting levels by day 8 after challenge.
An exact parallel series of experiments has been done to monitor the changes, in terms of both cell output and class II expression, in the primary response. Using sperm whale myoglobin as antigen and repeating the experiments as described above we were unable to demonstrate any significant alteration in either cell number or MHC class II expression . In contrast, subsequent secondary challenge with myoglobin in the same animals gave identical results as those described for OVA and PPD.
Flow cytometry confirms these data (Fig. 3) . scatter) . The increase in class II expression during secondary challenge occurs with every cell and not on minor populations.
By coupling mAb staining with cell cycle analysis it is possible to correlate cell surface phenotype with stages ofcell activation . Staining with PI and the monoclonals SW73.2 (anti-class II) and VPM 5 (anti-CDI) showed that the increase in DC class II expression and change in CDl phenotype was not associated with these cells entering cell cycle (data not shown) .
Alteration in the In Vitro Accessory Function of DC as a Result of In Vivo Antigenic Stimulation . In the companion article (5) we have reported that in vivo pulsed afferent DC are capable of stimulating autologous T cell lines, in the absence of exogenous antigen, in an antigen-specific manner. In this article we investigate their accessory potential in the presence of exogenous antigen. DC fractionated from afferent lymph were tested both before, and at daily intervals after, in vivo antigenic challenge to see whether their antigen-presenting ability was altered and if such alteration correlated with changes in the expression of either CD1 or MHC class II. Antigeninduced proliferation of PPD-and OVA-specific T cell lines and MLR assays were used to assess the in vitro antigen-presenting function of the DC. In all these experiments irradiated PBMC were used as a control for fractionated DC. Representative data from these experiments are shown in Figs. 5 and 6. Fig. 5 compares the effects of in vivo primary and in vivo secondary antigenic challenge (to sperm whale myoglobin) on the ability ofDC, isolated at different times after immune stimulation, to present alloantigen to allogeneic T cells and OVA to an OVA-specific T cell line. The same sheep were used for both the primary and secondary experiments and before the start of the secondary responses the animals were primed with, and shown to be responsive to, sperm whale myoglobin. It is clear from these data that the capacity to induce T cell proliferation by DC isolated during the in vivo primary responses does not vary significantly after antigen inoculation. In contrast is the effect of secondary in vivo challenge. Although the results with PBMC are unchanging, the proliferation of the T cell lines and allogeneic efferent cells cultured with DC is markedly increased in both the antigen-induced proliferation and MLR assays respectively. Fig. 6 further illustrates the ability of DC from in vivo stimulated afferent lymph, isolated during a secondary response to myoglobin, to stimulate in an MLR or OVAinduced proliferation assay. It is clear that DC induce a substantially greater proliferation than PBM, which is most noticeable at limiting accessory cell concentrations . 1 x 103 DC, isolated 4 and 5 d after in vivo challenge with myoglobin, support 18-20,000 cpm (MLR) and 15-16,000 cpm (OVA) proliferation, approximately fivefold greater than that initiated by DC from resting lymph (4,000 and 3,000 cpm, respectively). That number ofPBM did not induce proliferation in either assay. The modulation ofproliferation induced by DC correlates temporally with the differential expression of MHC class II and not CDl. The relative degree of in vitro function gradually declines to preinoculation levels by day 8. Identical results were obtained when PPD and OVA were used as the in vivo antigen and also when autologous efferent lymphocytes were used as responder cells in the antigen-induced proliferation assays . These data support the view that DC, activated during secondary antigenic challenge, have an increased capacity to present exogenous antigen.
Effect ofMonoclonalAnti-Class IIandAnti-CDI Monoclonals on In Kim DCFunction . To assess the role of class II and CDl expression on the antigen-presenting function of afferent lymph DC, titrations of purified Ig [or F(ab')2 of SW73.2] of the anti-class II and anti-CD1 monoclonals were added to the in vitro assays . The anti-class Il antibodies tested, SW73 .2 (IgG2a) and VPM 3 (IgM), totally inhibited lymphocyte proliferation in both assays, with DC taken from resting afferent lymph.
The enhanced proliferation found with the use of DC isolated at days 3, 5, and 8 after secondary antigenic challenge was also blocked. SW73 .2 and VPM 3 gave 50% inhibition at 10 ng/ml, and at a 1/10 dilution, respectively, with 100% inhibition at 10 Ag and at a 1/2 dilution (data not shown) . The addition of the anti-CD1 antibodies VPM 5, SBUT6, CC13, and CC14 had no effect at any time on either assay, even with supernatant dilutions as high as 1/2.
Discussion
In this article we examine the kinetic changes in afferent lymph cell output and phenotype that occur as a result of in vivo primary and in vivo secondary antigenic stimulation in the drainage area ofthe afferent lymphatic, and correlate these changes with alterations in in vitro immunological function of afferent lymph DC. Afferent lymph DC are defined as those cells ofdendritic morphology that constitutively express both MHC class II and the sheep analogue of CD1 (5).
Primary antigenic challenge stimulates no detectable alterations in afferent cell output or the numbers of cells expressing sIg, class II, or CDI, although dramatic changes occur in levels of CD1 expression by a large majority of individual DC. In vivo antigenic stimulation in primed animals was demonstrated to have profound effects on the quantitative expression of MHC class II, as well as CD1. If we assume one antibody binding site per class II molecule, the expression of class II on DC is increased from 3 x 105 molecules (channel number 196) to 1 .7 x 106 molecules (channel number >250) per cell as a result of antigenic challenge. This level of class II expression by sheep DC and its relative increase induced by exogenous stimuli are very similar to those shown for mouse epidermal Langerhans' cells (21) which seem to be the precursors of lymphoid DC (22) . Changes in class II expression by afferent lymphocytes are less marked, increasing from -1 x 105 (channel number 133) to 2 x 105 (channel number 164) . These data establish that the stimuli for the increase in class II occur in antigenically primed animals only. This strongly suggests that they arise from antigen-activated T cells. Cytokines from activated T cells have been shown to induce class II synthesis (23) . Candidate mediators therefore would include BSF1/IL-4 and IFN-, y, both of which have been shown to induce class II expression in nondividing cells (24) (25) (26) (27) . It is of interest to note that the rela-tive increase in class II expression by DC ( x 5-6) is much greater than for afferent lymphocytes (x 2). This raises the possibility that the class II expressed by DC and lymphocyte populations are qualitatively different. Afferent T cells for instance could be restricted in their expression of individual locus products. The alternative explanation, that the increase in class II expression is a result of cell division (28) , has been eliminated, as we have shown that the afferent lymph DC are not in cycle. There have been no previous descriptions of quantitative variations of CD1 expression; the stimuli for the changes in CD1 expression are, therefore, open to speculation . The data in this article illustrate that afferent lymph DC ofthe sheep, like those of the rat (29) , rabbit (30), pig (31) , and bovine (32) , can present soluble antigen to antigen-specific T cells as well as stimulating allogeneic lymphocytes in the primary MLR. The capacity of afferent DC to enhance in vitro lymphocyte proliferation seems also to correlate directly with increased class II expression but not with CD1. At day 5 after in vivo antigen, the DC express five-to sixfold the preinoculation levels of class II and, at limiting DC concentrations, are about fivefold as active in the proliferation assays . The main increase in dendritic cell expression of CD1 occurs by day 2, before any increase in class II and enhancement of antigen presentation . In addition, treatment ofthe cells with anti-class II antibodies, but not anti-CD1 antibodies, abrogates all in vitro accessory function, including that at the peak of the in vivo response.
Although class II expression is necessary for antigen presentation (33, 34 ) and cells such as macrophages and astrocytes can present antigen only after they have been induced to express class II (35, 36) , it is beginning to be clear that quantitative variation of expressed class II plays a central role in immune regulation (37) (38) (39) (40) and aberrant expression may contribute to autoimmune disease (41) . These data support the proposition that the magnitude ofT cell responses is related to the product of the concentrations of antigen and class II (42) . The function of CD1 expressed by DC is unclear, but in view of its differential expression during both primary and secondary responses, as well as its homology with both MHC class I and class II (43) , it is intriguing to speculate on its potential as an antigen-binding protein. In this article we document a temporal correlation between enhanced accessory function of DC and increases in class II expression, but antigenic stimulation almost certainly affects parameters other than CD1 and class II synthesis. IL-1, for instance, is produced as a result ofmany different stimuli (44) and has been shown to upregulate the stimulatory activity of DC (45) . In vivo stimulation could induce DC to secrete IL-1 or even express membrane IL-1 on the cell surface (46) . The results could also be explained by the fact that the enhanced capacity to induce a proliferative response in lymphocytes is mediated by IL-1 or similar molecules released by in vivo activated DC.
In summary, we describe in this article our approach to the study of the molecules associated with immune cell function . We describe the in vivo variation ofCD1 and class II expression by DC, implicating quantitative variations of class II expression in immune regulation in vivo. We also extend our knowledge to include those events that occur within the relevant physiological environment in vivo. Further work will concentrate on the differential expression ofthe products of the individual CD1 and class 11 genes by the distinct cell populations within the sheep lymphoid system .
Summary
The experiments described in this article characterize the phenotypic and functional changes in afferent lymph cell populations that occur as a result of in vivo immune stimulation. During the primary immune response (in antigen-naive sheep) there are very transient increases in level of CDl expression by subpopulations of dendritic cells (DC) but no alterations in cell kinetics or MHC class II expression . In contrast, secondary antigenic challenge (in primed sheep) into the drainage area of an afferent lymphatic causes profound changes in the cell output, characterized by a greater than threefold drop in total cell output on days 1-3 followed by an approximate fivefold rise on day 5. There is also a substantial increase in both the proportion of MHC class II-positive T lymphocytes (from 28 to 54%) and in the quantitative expression of class II by both DC and lymphocytes. Class II expression by DC increases five-to sixfold by day 5, while the level of expression of class II on lymphocytes approximately doubles. The increase in CDl expression during the secondary response is more prolonged than during the primary response, being detectable between days 2 and 6 after challenge. The rise in class II affects the whole DC population, in contrast to CD1 where the increase affects only a subpopulation of cells.
In terms of functional properties, afferent lymph DC isolated during a primary response show no alteration of their activity, whereas DC taken 4-5 d after secondary challenge are up to fivefold more active in their ability to present soluble antigen to primed autologous T cells and to antigen-specific cell lines as well as to stimulate in the MLR. The relative expression of class II correlates temporally with an increased capacity of DC to present antigen. Monoclonal anti-class II antibodies totally inhibit the in vitro assays but anti-CD1 antibodies have no effect . The previous paper (5) has demonstrated that afferent DC can associate with antigen in vivo and can present that antigen to antigen-specific T cells. This article extends our knowledge of DC biology and demonstrates that DC, activated during secondary in vivo immune responses, have an enhanced ability to present an antigen, unrelated to that used for challenge, to specific T cell lines. This enhancement correlates directly with quantitative variation of expressed class II and not CDl and suggests that this variation in class II expression plays a physiological role in in vivo immune regulation .
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